Toxicology

#Assay #Drug development #Drug toxicity #Preclinical development #Toxicology

Enhancing the predictability of drug toxicity and efficacy

There is an unmet clinical need in drug development for in vitro models that reduce the risk of drug-induced toxicity and late-stage drug attrition. In this webinar, hosted on May 26 2021, two expert speakers discuss how researchers can enhance the predictability of pre-clinical drug development. This webinar, Enhancing the predictability of… Read More

#Editor's Choice #News

#Assays #Clinical trials #Drug toxicity #Preclinical development #Toxicology

Driving the success of predictability in preclinical development 

The development of predictive preclinical assays is key to success in drug development. It is therefore critical to carefully construct biomarker studies using the most appropriate assays that better represent the complex physiology of disease for the reliable assessment of safety, efficacy, and dose predictions. To explore this topic further, Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases,… Read More

#Editor's Choice #News

#Biomedical research #Events #Life sciences #Toxicology

2021 Society of Toxicology ToxExpo

LifeNet Health LifeSciences, provider and collaborators in human in vitro biology and drug discovery optimisation, is highlighting innovative human cell and tissue-based research solutions at this year’s ToxExpo. The showcase includes the new, all-human Tri-Culture model, thyrocytes for use in 3D models and genotyped human hepatocytes. It can be found… Read More

#News

#Toxicology

In vitro models for assessing drug toxicity: new approaches and development

Karissa Cottier, PhD Research Scientist, BioIVT, ADME-Tox, examines the ongoing development and advances to ensure drug efficacy and safety Researchers evaluate the efficacy and safety profiles of drug candidates, including their potential to cause liver damage, when considering whether to advance them in development programs. Drug-induced liver injury (DILI) is a… Read More

#Exclusive Content

#Toxicology

Gentronix expands toxicology services to meet growing global demand

UK-based Contract Research Organisation (CRO) Gentronix – a specialist toxicology CRO based at Alderley Park – is expanding its service range to provide specialist services in the field of dermal toxicology, amidst increasing global demand that is driving further growth for the business. Gentronix’s comprehensive development and growth strategy has… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

High content screening in action: a powerful tool to identify novel antivirals and vaccines

By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Cell therapy #Clinical trials #Drug development #Drug targets #Gene therapy #Immunology #Immunology / Virology & Vaccines #Molecular medicine #Oncology #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Honing in on perfect targeting

Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 - Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known as personalised cancer vaccine therapy. Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Organic chemistry #Pharmokinetics #Precision medicine #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

The COVID-19 antiviral race: we’re all in this together

The COVID-19 antiviral race: we're all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Clinical specialities #Drug development #Enabling technologies #Flow Cytometry #Genetics / genomes #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead optimisation #Microfluidics #PCR #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Toxicology

Creating vaccines drop by drop

By Richard Gray The recent outbreak of COVID-19 has highlighted the need for fast and efficient development and production of vaccines for a whole gamut of pathogens, old and new. Microfluidics technologies can be used to accelerate the vaccine development process in a number of ways, not least in the… Read More

#Covid-19 #Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Pharmokinetics #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The CELL CULTURE innovations increasing drug discovery success

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 - Summer 2020 'Fail early, fail fast' has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet,… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomics #Genomics #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Collaborative Research Leads To New Understanding Of Biomarkers

Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the human body. Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Biochemistry #Bioengineering #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Stem Cell Differentiation

Stem Cell Differentiation By Dr Lilian Hook Stem cells are extraordinary cells, capable of both self-renewal and differentiation to mature somatic cells in vivo and in vitro (1,2). They have many features and advantages which could revolutionise drug development and healthcare applications. Stem cells offer a limitless, consistent supply of… Read More

#Archive

#Analysis #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Phenotypic Drug Discovery With High Content Screening

Phenotypic Drug Discovery With High Content Screening Sponsored by PerkinElmer Early drug discovery used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system - cells, tissue, or organisms - and asking the question, did this entity affect the phenotype? Target Based or Phenotypic… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Molecular medicine #Oncology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology

Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology Sponsored by Agilent This white paper discusses targeting energy metabolism for cancer therapeutic discovery using Agilent Seahorse XF technology. Abstract Altered energy metabolism is now recognized as a driver in many diseases. In cancer research, significant advances have… Read More

#Archive

#Academic #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cellular assays #Drug development #Drug discovery #Drug targets #Flow Cytometry #High Content Screening #High throughput screening #Immunology #Lead discovery #Pharmacology #RNA #Screening #Stem cells #Therapeutics #Toxicology

Advanced Therapeutic Antibody Discovery with Multiplexed Screening

Advanced Therapeutic Antibody Discovery with Multiplexed Screening Sponsored by Sartorius Antibody-based therapeutics are the fastest growing and most successful therapeutic modality for treating diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease. It is predicted that by the year 2020 there will be 70 therapeutic antibodies on the… Read More

#Archive

#Academic #Analysis #Assay development optimisation & technology #Cellular assays #Drug development #Drug discovery #Lead discovery #Lead optimisation #Preclinical #RNA #Screening #Target validation #Toxicology

Arctoris Ltd Successfully Moves into its New Global Headquarters in Oxford, UK

State-of-the art facility is home to the company’s next-generation, fully automated platform for drug discovery. Arctoris Ltd, the developer of the world’s first fully automated drug discovery platform, today opened the doors to its new global headquarters and state-of-the-art research and development (R&D) facility in Oxford,… Read More

#News